Abstract Library

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma

Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.

Conference:

Presenting Author: Zhang L

Authors: Falkman L, Zhang L, Welin S, Crona J,

Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,

#3877 Short fasting test as a reliable and effective tool to diagnose insulinoma

Introduction: Insulinomas are pancreatic NETs presenting with hypoglycaemia. Current guidelines for its diagnosis require a prolonged fasting test (72 hours), which implies hospitalization and is difficult to perform. It has been reported that up to 85% of insulinomas are diagnosed within a 24h fasting period.

Conference:

Presenting Author: Mikovic N

Authors: Mikovic N, Mazzilli R, Zamponi V, Russo F, Faggiano A,

Keywords: insulinoma, neuroendocrine pancreatic tumor, functioning NET, hypoglycaemia,

#3304 Ga-68/Lu-177 octreotate theranostic paradigm in metastatic Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumor with poor survival and significant propensity for metastasising. MCC is normally characterised by an up-regulation of somatostatin receptors (SSTR) which introduces the possibility for a targeted treatment approach using peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lenzo N

Authors: Falzone N, Meyrick D, Lee B, Lenzo N,

Keywords: peptide receptor radionuclide therapy, Merkel cell carcinoma, Lu-177 octreotate, Ac-225 octreotate,

#3113 Small cell neuroendocrine carcinoma of vagina - Rare, aggressive but curable?

Introduction: Small cell neuroendocrine carcinoma (SCNC) is a highly proliferative disease. It commonly affects lung and only 2.5-5% are extrapulmonary. SCNC of vagina is very rare with only 32 published cases in English literature.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Godinho J, Simões P, Leal-Costa L, Baptista C, Casa-Nova M,

Keywords: small cell neuroendocrine carcinoma, vagina, highly proliferative, rare disease,